A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

NCT00694785 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decided not to go forward with the study.

Conditions

Von Willebrand Disease

Interventions

DRUG: ARC1779
DRUG: ARC1779
DRUG: ARC1779
DRUG: ARC1779

Sponsor

Archemix Corp.